Navigation Links
Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
Date:7/9/2013

Westlake Village, CA (PRWEB) July 09, 2013

Cynvenio Biosystems, Inc., a cancer diagnostics company focused on the molecular analysis of tumor biomarkers derived from whole blood, today announced certification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 for its genomic sequencing laboratory in Westlake Village, California. This certification follows receipt of a California State license and allows the company to accept clinical samples from most U.S. states.

“Cynvenio has achieved an enviable level of operational excellence for its LiquidBiopsy service which includes the isolation of circulating tumor cells and their genomic analysis by next generation sequencing,” said Andreas Bakker, Ph.D., vice president of Operations at Cynvenio Biosystems, Inc.

Cynvenio Biosystems achieved California State licensing in April 2013, enabling the company to begin processing clinical samples. The company is currently accepting clinical samples and its LiquidBiopsy genomic profiling service is commercially available for all patients with solid tumors.

CMS manage and conduct inspections of CLIA laboratories as mandated by the Code of Federal Regulations (CFR 42 Part 493.2). The regulation was enacted to ensure consistent, accurate, and reliable clinical test results reporting from laboratories across the country used for the diagnosis, treatment, and/or prognosis of disease in human subjects. CLIA applies to all clinical laboratories operating in the U.S. and its territories and encompasses more than 200,000 clinical testing sites.

About Cynvenio’s LiquidBiopsy

The LiquidBiopsy service (http://www.liquidbiopsy.com) uses next generation sequencing to analyze tumor cells isolated from whole blood. The clinical information produced by LiquidBiopsy sequencing provides an understanding of the specific molecular pathways that are driving tumor growth. This analysis can help develop individualized treatment strategies earlier in the disease cycle when more options may be available, and can be useful in metastatic disease when tissue samples may no longer be reliable or easily obtainable.

The LiquidBiopsy process starts with Cynvenio’s self-contained 7.5mL blood sample kit which includes collection materials and pre-paid FedEx packaging for return delivery to the processing lab. Significantly, the kit can travel unrefrigerated for up to five days which enables Cynvenio to support international as well as US testing locations.

Upon receipt at the lab the sample is processed by CT-SEQ, a Cynvenio protocol for direct-isolation-to- next-generation-sequencing without whole genome amplification. CT-SEQ evaluates mutations across 50 oncogenes for the presence of over 2100 single point mutations with a sensitivity of 1%. The results are summarized in a genomic report that includes leading-edge, clinically relevant information on current and experimental treatments and diagnostics for each patient's tumor type, based on their specific molecular profile. This report can be a useful decision-support tool for physicians, and since LiquidBiopsy requires only a normal blood draw, it is suitable for longitudinal patient monitoring and complements traditional FFPE tissue sample analysis. The turnaround time for CT-SEQ is typically 7 days from sample receipt. In addition to clinical oncologists, academic and industry researchers will find CT-SEQ useful for biomarker discovery and real-time monitoring of patients in clinical trials.

“Achieving CLIA certification enables us to accept and report on a variety of clinical samples and is a major milestone in our company’s development,” commented André de Fusco, Cynvenio’s CEO. “We are enthusiastic about LiquidBiopsy’s global reach and our ability to support partners worldwide in their fight against cancer.”

About Cynvenio Biosystems, Inc.

Cynvenio Biosystems, Inc. is a molecular diagnostics company dedicated to the early detection and targeted treatment of cancer. Cynvenio has developed and deployed the LiquidBiopsy system to enable realtime monitoring of tumor cell-associated mutations from a simple blood draw. This information may be used by physicians, academic centers, and drug developers to assist in the definition of treatment cycles for individual patients, the selection of patients for drug trials and to monitor patient response at any stage of disease.

Cynvenio’s CLIA service lab is based in Westlake Village, California. To find out more about the company please visit http://www.liquidbiopsy.com.

LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10909343.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
2. Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series
3. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
4. AyoxxA Biosystems Closes Series A Financing Round
5. Aushon BioSystems and AH diagnostics Sign Distribution Deal for Scandinavia
6. Aushon BioSystems and AH diagnostics unterzeichnen Distributionsvertrag für Skandinavien
7. Lucas Bagnell Varga LLC Secures $17.4 Million Award For Former Applied Biosystems Executives
8. Genesis Biosystems Unveils Innovative Skin Treatment at Esthétique SPA International Trade Show
9. Indigo Biosystems Nominated for Two TechPoint Mira Awards for Technology Excellence and Innovation
10. Indigo Biosystems Among “Best Places to Work” in Indiana
11. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen ... the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff ... of Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, ...
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... La. (PRWEB) , ... March 23, 2017 , ... ... industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as ... customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has ...
(Date:3/22/2017)... 2017  Ascendis Pharma A/S (Nasdaq: ASND), a ... to address significant unmet medical needs in rare ... year ended December 31, 2016. ... as we broadened our pipeline and pursued our ... company with an initial focus on endocrinology," said ...
Breaking Biology Technology:
(Date:3/9/2017)... March 9, 2017 4Dx has publicly released ... Imaging Workshop at the University of Pennsylvania. Founder and ... deliver the latest data to world leaders in lung ... together leaders at the forefront of the industry to ... "The quality of the imaging is ...
(Date:3/2/2017)... , March 2, 2017 Summary ... understand Perrigo and its partnering interests and activities since 2010. ... Read ... Deals and Alliance since 2010 report provides an in-depth insight ... life sciences companies. On demand company reports are ...
(Date:2/28/2017)... ANGELES , Feb. 28, 2017   Acuant ... verification software globally, announces significant enhancements to new and ... May 2016. New products include mobile and desktop Acuant ... DocX TM - a real time manual review ... core idScan® technology provides the fastest and most accurate ...
Breaking Biology News(10 mins):